肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议

2020-06-11 MedSci原创 MedSci原创

双特异性抗体Car-T细胞疗法信达生物
关注

瑞士制药巨头罗氏公司已与苏州信达生物达成协议，共同开发针对血液瘤和实体癌的通用CAR-T细胞疗法和2:1 T细胞双特异性抗体。

瑞士制药巨头罗氏公司已与信达生物（Innovent Biologics）达成协议，共同开发针对血液瘤和实体癌的通用CAR-T细胞疗法和2:1 T细胞双特异性抗体（包含3个可与抗原结合的结构域：1个与T细胞抗原结合，2个与肿瘤抗原结合）。

罗氏的2:1 T细胞双特异性抗体（图片来源：罗氏）

根据该协议的条款，总部位于中国苏州的信达生物将支付使用罗氏技术的前期费用以及开发、商业里程碑付款和特许权使用费。

如果所有产品均已成功开发并商业化，罗氏将向Innovent支付高达1.4亿美元，再加上高达19.6亿美元的额外开发、批准和销售里程碑付款。罗氏还将为选择开发和商业化的每种产品支付两位数的专利使用费。

Innovent董事长兼首席执行官俞德超表示：“几年前，Innovent首次进入细胞疗法领域，通过与罗氏的合作，我们将迈出更大胆的一步，将基于罗氏新颖的通用CAR-T细胞技术来增强我们的细胞疗法平台，并继续利用罗氏的2：1 T细胞双特异性抗体平台开发和商业化新的双特异性分子。”

2015年，Innovent与礼来公司签署了一项协议，共同开发至少三种实验性抗癌药物，从而在中国开发并最终批准了其癌症免疫疗法抗PD-L1单抗Tyvyt（sintilimab）。

Tyvyt于2018年12月获得中国国家药品监督管理总局批准用于治疗复发和难治性经典霍奇金淋巴瘤（cHL）。

原始出处：

http://www.pmlive.com/pharma_news/roche,_innovent_sign_$2bn_bispecifics_deal_1341997

评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
    2021-05-17 jinweidong

    #特异性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
    2021-03-23 仁者大医

    #CAR-#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
    2020-06-14 研发小兵

    双特异性抗体是热点，但是也不一定都有效！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
    2020-06-13 changjitao2009

    #Car-T细胞疗法#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
    2020-06-13 yytms

    #信达生物#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
    2020-06-13 heli0118

    #T细胞疗法#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1899388, encodeId=cb661899388eb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 17 07:47:39 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781365, encodeId=4c171e8136563, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Mar 23 19:47:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025812, encodeId=77231025812e9, content=双特异性抗体是热点，但是也不一定都有效！, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Jun 14 20:47:39 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4077, encryptionId=2acd40e7ba, topicName=Car-T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27375, encryptionId=9df42e37593, topicName=信达生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26526732817, createdName=yytms, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478041, encodeId=a7aa14e80412c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526473, encodeId=ac0015264e386, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Jun 13 11:47:39 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
    2020-06-13 hyf032

    #特异性抗体#

    0

相关资讯

Glenmark双特异性抗体GBR 1342治疗多发性骨髓瘤，喜获FDA孤儿药物指定

Glenmark Pharmaceuticals宣布其双特异性药物抗体候选GBR 1342用于先前已接受过治疗的多发性骨髓瘤患者，获得美国食品和药物管理局（FDA）的孤儿药物指定。

双特异性抗体：过去，现在与未来

双特异性抗体：过去，现在与未来，是目前最为全面的介绍与综述，包括机制，工艺，平台，挑战，用途

双特异性抗体Faricimab治疗AMD的Ⅲ期数据公布，16周仅需给药1次

AMD是老年群体中常见的一种眼部疾病，影响视力的中心区域——黄斑，这是人视觉最敏锐和最关键的部位。AMD分为“湿性（wet）”和“干性&rd

安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果

Amgen宣布其双特异抗体BLINCYTO（blinatumomab）（同时靶向CD3和CD19）针对小儿复发B细胞急性淋巴细胞白血病（ALL）的全球多中心3期临床试验（20120215）的中期分析结果已达到了无事件生存的主要终点。

JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%

在胸部肿瘤学杂志（JTO）上公布的最新研究中，德国默克（Merck KGaA）的在研新药M7824公布的最新临床数据引起轰动！这是一款在研的双功能性免疫疗法，能同时靶向PD-L1通路和TGF-&szl

合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元

里程碑付款可能超过30亿美元